We are thrilled to share that CardiaMetrics has been featured in La Gazette du Laboratoire! The article highlights our journey, our innovative implantable device for heart failure patients, and the team driving this technology forward.
Founded in 2023, CardiaMetrics builds on six years of R&D to develop a subcutaneous implantable system that monitors patients’ vital signs daily, anticipates cardiac decompensations, and improves quality of life at home. The Gazette Labo article details our transition from SentinHealth to CardiaMetrics, our shift from a gastric-based device to a subcutaneous approach inspired by implantable Holters, and the strong multidisciplinary team supporting this ambitious project.
The article also emphasizes our clinical ambitions, including ongoing trials at the CHU de Caen to validate both the safety and performance of the device. With a robust regulatory and quality framework, our system is designed to comply with international standards, ensuring reliable, clinically actionable insights for healthcare professionals.
We are proud to be recognized for our work in advancing remote monitoring for heart failure, a critical medical need affecting millions worldwide. This press coverage is a great opportunity for readers to learn more about our technology, team, and vision.
📖 Read the full article on La Gazette Labo here: CardiaMetrics, une startup spécialisée dans le développement d’un dispositif médical automatique implantable pour la télésurveillance de patients atteints d’insuffisance cardiaque.